Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 237

1.

Eculizumab in secondary atypical haemolytic uraemic syndrome.

Cavero T, Rabasco C, López A, Román E, Ávila A, Sevillano Á, Huerta A, Rojas-Rivera J, Fuentes C, Blasco M, Jarque A, García A, Mendizabal S, Gavela E, Macía M, Quintana LF, María Romera A, Borrego J, Arjona E, Espinosa M, Portolés J, Gracia-Iguacel C, González-Parra E, Aljama P, Morales E, Cao M, Rodríguez de Córdoba S, Praga M.

Nephrol Dial Transplant. 2017 Mar 1;32(3):466-474. doi: 10.1093/ndt/gfw453.

2.

Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.

Ito S, Hidaka Y, Inoue N, Kaname S, Kato H, Matsumoto M, Miyakawa Y, Mizuno M, Okada H, Shimono A, Matsuda T, Maruyama S, Fujimura Y, Nangaku M, Kagami S.

Clin Exp Nephrol. 2019 Jan;23(1):112-121. doi: 10.1007/s10157-018-1610-2. Epub 2018 Jul 23.

3.

Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.

Kato H, Miyakawa Y, Hidaka Y, Inoue N, Ito S, Kagami S, Kaname S, Matsumoto M, Mizuno M, Matsuda T, Shimono A, Maruyama S, Fujimura Y, Nangaku M, Okada H.

Clin Exp Nephrol. 2019 Jan;23(1):65-75. doi: 10.1007/s10157-018-1609-8. Epub 2018 Jun 29.

4.

Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.

Mallett A, Hughes P, Szer J, Tuckfield A, Van Eps C, Cambell SB, Hawley C, Burke J, Kausman J, Hewitt I, Parnham A, Ford S, Isbel N.

Intern Med J. 2015 Oct;45(10):1054-65. doi: 10.1111/imj.12864.

PMID:
26247170
5.

Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.

Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, Menne J, Minetti EE, Provôt F, Rondeau E, Ruggenenti P, Weekers LE, Ogawa M, Bedrosian CL, Legendre CM.

Am J Kidney Dis. 2016 Jul;68(1):84-93. doi: 10.1053/j.ajkd.2015.12.034. Epub 2016 Mar 21.

6.

Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab.

Ikeda T, Okumi M, Unagami K, Kanzawa T, Sawada A, Kawanishi K, Omoto K, Ishida H, Tanabe K.

Nephrology (Carlton). 2016 Jul;21 Suppl 1:35-40. doi: 10.1111/nep.12768.

PMID:
26970541
7.

Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.

Duineveld C, Verhave JC, Berger SP, van de Kar NCAJ, Wetzels JFM.

Am J Kidney Dis. 2017 Dec;70(6):770-777. doi: 10.1053/j.ajkd.2017.06.024. Epub 2017 Aug 16.

PMID:
28821363
8.

Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.

Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NC, Vande Walle J, Ogawa M, Bedrosian CL, Licht C.

Kidney Int. 2016 Mar;89(3):701-11. doi: 10.1016/j.kint.2015.11.026. Epub 2016 Jan 28.

9.

Prevention and treatment of atypical haemolytic uremic syndrome after kidney transplantation.

Okumi M, Tanabe K.

Nephrology (Carlton). 2016 Jul;21 Suppl 1:9-13. doi: 10.1111/nep.12776. Review.

PMID:
26988663
10.

Complement-mediated thrombotic microangiopathy secondary to sepsis-induced disseminated intravascular coagulation successfully treated with eculizumab: A case report.

Abe T, Sasaki A, Ueda T, Miyakawa Y, Ochiai H.

Medicine (Baltimore). 2017 Feb;96(6):e6056. doi: 10.1097/MD.0000000000006056.

11.

Eculizumab in atypical haemolytic uraemic syndrome with severe cardiac and neurological involvement.

Hu H, Nagra A, Haq MR, Gilbert RD.

Pediatr Nephrol. 2014 Jun;29(6):1103-6. doi: 10.1007/s00467-013-2709-z. Epub 2013 Dec 8.

PMID:
24317637
12.

An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.

Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyó JM, Macía M, Mendizábal S, Praga M, Román E, Torra R, Valdés F, Vilalta R, Rodríguez de Córdoba S.

Nefrologia. 2015;35(5):421-47. doi: 10.1016/j.nefro.2015.07.005. Epub 2015 Oct 9. English, Spanish.

13.

Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab.

Servais A, Devillard N, Frémeaux-Bacchi V, Hummel A, Salomon L, Contin-Bordes C, Gomer H, Legendre C, Delmas Y.

Nephrol Dial Transplant. 2016 Dec;31(12):2122-2130. Epub 2016 Sep 1.

PMID:
27587606
14.

Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.

Cugno M, Gualtierotti R, Possenti I, Testa S, Tel F, Griffini S, Grovetti E, Tedeschi S, Salardi S, Cresseri D, Messa P, Ardissino G.

J Thromb Haemost. 2014 Sep;12(9):1440-8. doi: 10.1111/jth.12615. Epub 2014 Jul 16.

15.

Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.

Yamamoto T, Watarai Y, Futamura K, Okada M, Tsujita M, Hiramitsu T, Goto N, Narumi S, Takeda A, Kobayashi T.

Transplant Proc. 2017 Jan - Feb;49(1):159-162. doi: 10.1016/j.transproceed.2016.10.013.

PMID:
28104125
16.

Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review.

de Holanda MI, Pôrto LC, Wagner T, Christiani LF, Palma LMP.

Clin Rheumatol. 2017 Dec;36(12):2859-2867. doi: 10.1007/s10067-017-3823-2. Epub 2017 Sep 13. Review.

PMID:
28905254
17.

Suspected atypical haemolytic uraemic syndrome in two post-partum patients with foetal-death in utero responding to eculizumab.

Chua J, Paizis K, He SZ, Mount P.

Nephrology (Carlton). 2017 Feb;22 Suppl 1:18-22. doi: 10.1111/nep.12935. Review.

PMID:
28176472
18.

Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab.

Asif A, Nayer A, Haas CS.

J Nephrol. 2017 Jun;30(3):347-362. doi: 10.1007/s40620-016-0357-7. Epub 2016 Nov 15. Review.

19.

Absence of thrombocytopaenia and/or microangiopathic haemolytic anaemia does not reliably exclude recurrence of atypical haemolytic uraemic syndrome after kidney transplantation.

Krishnan AR, Siva B, Chakera A, Wong G, Wong D, Lim WH.

Nephrology (Carlton). 2017 Feb;22 Suppl 1:28-31. doi: 10.1111/nep.12937. Review.

PMID:
28176477
20.

Practical issues in using eculizumab for children with atypical haemolytic uraemic syndrome in the acute phase: A review of four patients.

Terano C, Ishikura K, Hamada R, Yoshida Y, Kubota W, Okuda Y, Shinozuka S, Harada R, Iyoda S, Fujimura Y, Hamasaki Y, Hataya H, Honda M.

Nephrology (Carlton). 2018 Jun;23(6):539-545. doi: 10.1111/nep.13054.

PMID:
28387984

Supplemental Content

Support Center